Progress on the Beam Energy Monitor for the SPIRAL2 Accelerator.
The first part of the SPIRAL2 project entered last year in the end of the construction phase at GANIL in France. The facility will be composed by an ion source, a deuteron/proton source, a RFQ and a superconducting linear accelerator. The driver is planned to accelerate high intensities, up to 5 mA and 40 MeV for the deuteron beams. A monitoring system was built to measure the beam energy on the BTI line (Bench of Intermediate Test) at the exit of the RFQ. As part of theMEBT commissioning, the beamenergy will be measured on the BTI with an Epics monitoring application. At the exit of the LINAC, another system will have to measure and control the beam energy. The control consists in ensuring that the beam energy stays under a limit by taking account of the measurement uncertainty. The energy is measured by a method of time of flight; the signal is captured by non-intercepting capacitive pick-ups. This paper describes the BTI monitor interface and presents the system evolution following the design review.
Initial commissioning of ion beams at SPIRAL2
The official reception of the SPIRAL2 accelerator 
building occurred in October 2014. In parallel, the 
installation of the accelerator components has started in 
June 2013. The first part of the beam commissioning, 
including the ECR sources, the LEBTs and the 88 MHz 
RFQ should start in December, with an injection in the 
Linac by mid-2015. This paper describes the status of the 
accelerator components and installation, and the 
philosophy retained to commission the light and heavy 
ion beams at various required final energies.
Community refinement of glaucoma referrals
AbstractAim To describe a Manchester-based glaucoma referral refinement scheme designed to reduce the number of false-positive referrals to the hospital eye service. To report on the first years results of this scheme and its financial costs to the NHS.Methods Patients with suspected glaucoma, instead of being referred to their GP and then on to the hospital eye service, were referred to a group of specially trained community optometrists working to an agreed set of referral criteria. Those patients who did not meet the referral criteria were returned to the referring optometrist, while those who met the referral criteria were referred directly to Manchester Royal Eye Hospital. The patient's GP was informed in all cases.Results The number of suspect glaucoma cases referred to the Manchester Royal Eye Hospital was reduced by 40%. This figure is close to the percentage of false-positive referrals measured at Manchester Royal Eye Hospital prior to the onset of this study. The information accompanying referral has been improved and the scheme produces a small financial cost saving to the NHS of approximately £17 per patient.Conclusion Community refinement of suspect glaucoma offers some important benefits over the current referral pathway.